Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

Affiliations

¹ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
² Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center.
³ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center.
⁴ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
⁶ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
⁷ Division of Pharmacy, The University of Texas MD Anderson Cancer Center.
⁸ Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Comment

Sattva S Neelapu et al. Nat Rev Clin Oncol. 2018 Apr.

. 2018 Apr;15(4):218.

doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13.

¹ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
² Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center.
³ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center.
⁴ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
⁶ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
⁷ Division of Pharmacy, The University of Texas MD Anderson Cancer Center.
⁸ Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Comment on

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Neelapu SS, et al. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Nat Rev Clin Oncol. 2018. PMID: 28925994 Free PMC article. Review.
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.
Teachey DT, Bishop MR, Maloney DG, Grupp SA. Teachey DT, et al. Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.19. Epub 2018 Feb 13. Nat Rev Clin Oncol. 2018. PMID: 29434335 No abstract available.

1. Teachey DT et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL. Nat. Rev. Clin. Oncol. https://doi.org/10.1038.org/nrclinonc.2017.19 (2018). - DOI - PubMed
1. Neelapu SS et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018). - PMC - PubMed
1. Schuster SJ et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of cTL0 19 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 130, 577 (2017).
1. Abramson J et al. High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood 130, 581 (2017). - PubMed
1. Grupp SA et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood 128, 221 (2016).